Tier 2 — strong

Nicotinamide Riboside Supplementation Benefits in Patients With Werner Syndrome: A Double-Blind Randomized Crossover Placebo-Controlled Trial

Shoji M, Kato H, Koshizaka M, Kaneko H, Baba Y, Ishikawa T, Teramoto N, Kinoshita D, Yamaguchi A, Maeda Y, Inaba Y, Shiko Y, Ozawa Y, Bohr VA, Maezawa Y, Yokote K
Aging cell 2025 24; 8; e70093

Bibliography

PubMed
PMID 40459998
PubMed Central
PMC12341770
DOI
10.1111/acel.70093
Funding
Japanese public research support, including MHLW, JSPS and AMED programs. ChromaDex supplied NR and placebo.
Competing interests
The authors declared no competing interests and described the ChromaDex supply agreement and absence of company involvement in study conduct or reporting.

Study snapshot

DesignRandomized placebo-controlled human trial
ModelHuman participants
Sample11 enrolled; 9 randomized with Werner syndrome
InterventionNR 1000 mg/day versus placebo
Duration26 weeks per treatment period; 52 weeks total
EndpointsSafety; arterial stiffness; skin ulcers

What the study showed, in plain terms

NR was tolerated in this very small rare-disease trial, with favorable signals in arterial-stiffness and skin-ulcer measures.

Key findings

NR was tolerated in this very small rare-disease trial, with favorable signals in arterial-stiffness and skin-ulcer measures.

What this study can and cannot tell us

Exploratory outcomes in nine randomized patients and no washout period. Results do not establish benefit in usual aging or prevention of kidney disease.

Related papers in the corpus

Tier 2
Safety and efficacy of individualised exercise and NAD+ precursor supplementation in patients with Friedreich's ataxia in the USA: a single-centre, 2 × 2 factorial, randomised controlled trial
Lin KY et al. · The Lancet. Neurology · 2026
Tier 4
Effects of nicotinamide riboside in mitochondrial DNA disease
Katherine R. Schon et al. · Genome Medicine · 2026
Tier 4
Long-Term Nicotinamide Riboside Use Improves Coordination and Eye Movements in Ataxia Telangiectasia
Presterud R et al. · Movement disorders : official journal of the Movement Disorder Society · 2024
Tier 4
ACAD9 treatment with bezafibrate and nicotinamide riboside temporarily stabilizes cardiomyopathy and lactic acidosis
Van Hove JLK et al. · Mitochondrion · 2024
Tier 4
Nicotinamide Riboside for Ataxia Telangiectasia: A Report of an Early Treated Individual
Steinbrücker K et al. · Neuropediatrics · 2023
Tier 4
S-adenosylmethionine and nicotinamide riboside therapy in Arts syndrome: A case report and literature review
Lee A et al. · JIMD reports · 2023

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology